Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

Abstract:

AIMS:Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to determine the proportion of breast cancer that could be candidates for rapamycin treatment and to elucidate the clinicopathologic characteristics and prognosis of potentially rapamycin-sensitive tumors. METHODS:We evaluated the expressions of PTEN, p-Akt and p-S6K1 by performing immunohistochemistry in 122 breast cancer tissues. We analyzed the association of the expression of these proteins with the cliniopathologic variables and the disease-free survival. RESULTS:PTEN negative tumors, p-Akt expressing tumors and p-S6K1 expressing tumors constituted 4.1% (5/122), 41.0% (50/122), and 36.1% (44/122) of the total tumors, respectively. The proportion of tumors that met the criteria of rapamycin sensitivity was 54.9% (67/122). We could not find any significant correlation between the expression of these proteins and the other prognostic factors. However, the prognosis of tumors with a p-S6K1 expression was significantly worse than that of the p-S6K1 negative tumors. CONCLUSION:Based on the status of the PTEN, p-Akt and p-S6K1 expressions as predictors of rapamycin sensitivity, this study suggested that over 50% of breast cancer patients could be potential candidates for rapamycin treatment. In addition, the p-S6K1 expression may constitute an independent prognostic factor for disease-free survival.

authors

Noh WC,Kim YH,Kim MS,Koh JS,Kim HA,Moon NM,Paik NS

doi

10.1007/s10549-007-9746-x

subject

Has Abstract

pub_date

2008-08-01 00:00:00

pages

477-83

issue

3

eissn

0167-6806

issn

1573-7217

journal_volume

110

pub_type

杂志文章
  • Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients.

    abstract::The present study consists of 1,238 women with unilateral breast cancer treated with modified radical mastectomy living in the geographic area of Haukeland Hospital. Their weight and height had been measured years before presentation of the disease. Age-adjusted Quetelet's index (weight/height2) showed that obese wome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807157

    authors: Maehle BO,Tretli S

    更新日期:1996-01-01 00:00:00

  • Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004.

    abstract::Breast cancer has emerged as the most frequent malignancy among Korean women. Its clinical features have become closer to those now observed in Western countries. We performed this study to evaluate the chronological changes in Korean breast cancer characteristics and reproductive factors from 1996 to 2004. A nationwi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-006-9188-x

    authors: Ahn SH,Yoo KY,Korean Breast Cancer Society.

    更新日期:2006-09-01 00:00:00

  • Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

    abstract:PURPOSE:Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on abs...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05106-7

    authors: Patel DA,Xi J,Luo J,Hassan B,Thomas S,Ma CX,Campian JL

    更新日期:2019-04-01 00:00:00

  • Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.

    abstract::Expression of HOX transcript antisense intergenic RNA (HOTAIR)--a long non-coding RNA--has been examined in a variety of human cancers, and overexpression of HOTAIR is correlated with poor survival among breast, colon, and liver cancer patients. In this retrospective study, we examine HOTAIR expression in 164 primary ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2776-7

    authors: Sørensen KP,Thomassen M,Tan Q,Bak M,Cold S,Burton M,Larsen MJ,Kruse TA

    更新日期:2013-12-01 00:00:00

  • Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.

    abstract::Conflicting theories of epithelial carcinogenesis disagree on the clonal composition of primary tumors and on the time at which metastases occur. In order to study the spatial distribution of disparate clonal populations within breast carcinomas and the extent of the genetic relationship between primary tumors and reg...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9317-6

    authors: Torres L,Ribeiro FR,Pandis N,Andersen JA,Heim S,Teixeira MR

    更新日期:2007-04-01 00:00:00

  • Chromosome 11q13 markers and D-type cyclins in breast cancer.

    abstract::One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00682720

    authors: Peters G,Fantl V,Smith R,Brookes S,Dickson C

    更新日期:1995-01-01 00:00:00

  • Association of RAD51C germline mutations with breast cancer among Bahamians.

    abstract:PURPOSE:RAD51C is known as an ovarian cancer gene; however, its role in breast cancer susceptibility is less clear. As part of a larger study, we assessed the role of germline RAD51C mutations in breast cancer development. METHODS:We studied 387 unselected, BRCA1- and BRCA2-negative, Bahamian breast cancer cases and 6...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05872-3

    authors: Bagherzadeh M,Szymiczek A,Donenberg T,Butler R,Hurley J,Narod SA,Akbari MR

    更新日期:2020-11-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract::Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1946-8

    authors: Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期:2012-07-01 00:00:00

  • Cellular localisation by in situ hybridisation of cathepsin D, stromelysin 3, and urokinase plasminogen activator RNAs in breast cancer.

    abstract::We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinoma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806676

    authors: Escot C,Zhao Y,Puech C,Rochefort H

    更新日期:1996-01-01 00:00:00

  • The value of embedding: integrated palliative care for patients with metastatic breast cancer.

    abstract:PURPOSE:The American Society of Clinical Oncology recommends concurrent palliative care (PC) for patients with metastatic cancer. Recent data show benefits of early PC (at least 90 days before death). However, little is known about PC among patients who die from metastatic breast cancer. METHODS:Patients with metastat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-017-4556-2

    authors: Rabow M,Small R,Jow A,Majure M,Chien A,Melisko M,Belkora J,Esserman LJ,Rugo H

    更新日期:2018-02-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract::In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00713399

    authors: Jordan VC

    更新日期:1995-01-01 00:00:00

  • Health disparities in breast cancer: biology meets socioeconomic status.

    abstract::Breast cancer is the most common cancer in women worldwide, accounting for just over 1 million new cases annually. Population-based statistics show that globally, when compared to whites, women of African ancestry (AA) tend to have more aggressive breast cancers that present more frequently as estrogen receptor negati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-010-0827-x

    authors: Dunn BK,Agurs-Collins T,Browne D,Lubet R,Johnson KA

    更新日期:2010-06-01 00:00:00

  • Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.

    abstract::While overall survival (OS) has historically been the primary endpoint for clinical trials in oncology, progression-free survival (PFS) has gained acceptance as a valuable surrogate endpoint. However, there are no known published reports about the value of PFS from the patient's perspective. We developed a questionnai...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2734-4

    authors: Hurvitz SA,Lalla D,Crosby RD,Mathias SD

    更新日期:2013-12-01 00:00:00

  • Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

    abstract:PURPOSE:To determine the influence of race on breast cancer treatment and on recurrence and breast cancer specific death. PATIENTS AND METHODS:The study population consisted of 6,054 African-American or white women who were diagnosed with breast cancer and received at least one of the treatments including mastectomy o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9337-2

    authors: Shen Y,Dong W,Esteva FJ,Kau SW,Theriault RL,Bevers TB

    更新日期:2007-05-01 00:00:00

  • Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.

    abstract::This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-004-4384-z

    authors: Kusama M,Miyauchi K,Aoyama H,Sano M,Kimura M,Mitsuyama S,Komaki K,Doihara H

    更新日期:2004-11-01 00:00:00

  • Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.

    abstract:PURPOSE:Estrogen exposure is involved in both breast cancer susceptibility and the prognosis in patients with breast cancer. Aromatase is involved in the production of estrogens, and altered expression of it might be associated with the prognosis. The aim of this study was to examine the effect of single nucleotide pol...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9822-2

    authors: Fasching PA,Loehberg CR,Strissel PL,Lux MP,Bani MR,Schrauder M,Geiler S,Ringleff K,Oeser S,Weihbrecht S,Schulz-Wendtland R,Hartmann A,Beckmann MW,Strick R

    更新日期:2008-11-01 00:00:00

  • LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients.

    abstract::Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in breast cancer. We analyzed the prognostic impact of LOXL2 for breast cancer patients and investigated the role of LOXL2 in breast cancer cell lines. Immunohistochemical study of LOXL2 expression was done in samples from 309 patients. Surviv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2662-3

    authors: Ahn SG,Dong SM,Oshima A,Kim WH,Lee HM,Lee SA,Kwon SH,Lee JH,Lee JM,Jeong J,Lee HD,Green JE

    更新日期:2013-08-01 00:00:00

  • Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women.

    abstract::In previous investigations of adolescent activity recalled in adulthood, modest reductions in risk of benign breast disease (BBD) and premenopausal breast cancer were seen with moderate-strenuous activity during high school. We therefore investigated physical activity, walking, and recreational inactivity (watching TV...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3055-y

    authors: Berkey CS,Tamimi RM,Willett WC,Rosner B,Lindsay Frazier A,Colditz GA

    更新日期:2014-08-01 00:00:00

  • Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02).

    abstract:PURPOSE:To evaluate the loco-regional recurrence (LRR) rate after breast-conserving surgery without postoperative radiotherapy (RT) for ductal carcinoma in situ (DCIS) of the breast. METHODS:Between 2000 and 2010, 311 DCIS patients from 9 institutions were analyzed retrospectively. The median age was 47 (range, 20-82)...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-017-4111-1

    authors: Kim K,Jung SY,Shin KH,Kim JH,Han W,Lee HB,Huh SJ,Choi DH,Park W,Ahn SD,Kim SS,Kim JH,Suh CO,Kim YB,Kim IA,Kim S,Kim YJ

    更新日期:2017-02-01 00:00:00

  • Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.

    abstract:OBJECTIVES:Improvements in the life expectancy of women with breast cancer raise important questions how to improve quality of life (QoL) for women sustaining complications and side effects of cancer treatment. The presented study examined the prevalence of arm morbidity in a cohort of primary breast cancer patients ov...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9247-3

    authors: Albert US,Koller M,Kopp I,Lorenz W,Schulz KD,Wagner U

    更新日期:2006-12-01 00:00:00

  • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.

    abstract::Tamoxifen is metabolized into endoxifen, a potent antagonist of the estrogen receptor, in part through cytochrome p450 (CYP) 2D6. Genotypic variation in CYP2D6 affects endoxifen levels, and some have argued that patients who do not efficiently metabolize tamoxifen might wish to consider alternative hormonal treatments...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-013-2700-1

    authors: Ruddy KJ,Desantis SD,Gelman RS,Wu AH,Punglia RS,Mayer EL,Tolaney SM,Winer EP,Partridge AH,Burstein HJ

    更新日期:2013-10-01 00:00:00

  • Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

    abstract:PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05479-3

    authors: Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

    更新日期:2020-01-01 00:00:00

  • Common genetic polymorphisms of microRNA biogenesis pathway genes and risk of breast cancer: a case-control study in Korea.

    abstract::Recent compelling evidence indicates that mutation, aberrant expression, and dysregulation of microRNA (miRNA) biogenesis are implicated in cancer development and progression. Based on the important role of miRNA biogenesis pathway in carcinogenesis, we hypothesized that genetic variations in this pathway genes may pl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1656-2

    authors: Sung H,Lee KM,Choi JY,Han S,Lee JY,Li L,Park SK,Yoo KY,Noh DY,Ahn SH,Kang D

    更新日期:2011-12-01 00:00:00

  • Protein production by osteoblasts: modulation by breast cancer cell-derived factors.

    abstract::Breast cancer cells (BCC) frequently metastasize to bone where they may cause tumor-induced osteolysis (TIO). While the important eroding role of the osteoclasts in TIO is well admitted, the possibility that BCC and/or osteoblasts activated by tumoral factors could also directly degrade bone matrix in this pathology h...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006408916224

    authors: Lacroix M,Marie PJ,Body JJ

    更新日期:2000-05-01 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract::Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01807591

    authors: Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期:1983-01-01 00:00:00

  • Obesity and subcutaneous fat patterning in relation to survival of postmenopausal breast cancer patients participating in the DOM-project.

    abstract::The effect of obesity and fat distribution on survival of breast cancer patients was studied prospectively in 241 women with a natural menopause who participated in a breast cancer screening project, the DOM-project in Utrecht, The Netherlands. Mean follow-up time was 9.1 years and endpoint of interest was death from ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00665785

    authors: den Tonkelaar I,de Waard F,Seidell JC,Fracheboud J

    更新日期:1995-05-01 00:00:00

  • Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.

    abstract::In contrast to antigen-specific alphabeta-T cells (adaptive immune system), gammadelta-T cells can recognize and lyse malignantly transformed cells almost immediately upon encounter in a manner that does not require the recognition of tumor-specific antigens (innate immune system). Given the well-documented capacity o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0527-6

    authors: Beck BH,Kim HG,Kim H,Samuel S,Liu Z,Shrestha R,Haines H,Zinn K,Lopez RD

    更新日期:2010-07-01 00:00:00

  • Effects of tea consumption and the interactions with lipids on breast cancer survival.

    abstract:PURPOSE:The effect of tea consumption on breast cancer survival remained to be explored. Meanwhile, green tea favorably facilitates lipid metabolisms in breast cancer survivors. This study aimed to examine the effect of tea consumption and the interactions with lipids on breast cancer survival. METHODS:A total of 1551...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05253-5

    authors: Zhang JY,Liao YH,Lin Y,Liu Q,Xie XM,Tang LY,Ren ZF

    更新日期:2019-08-01 00:00:00

  • Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.

    abstract::Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-006-9444-0

    authors: Minisini AM,Pauletto G,Bergonzi P,Fasola G

    更新日期:2007-10-01 00:00:00

  • Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison.

    abstract:INTRODUCTION:Since older patients with breast cancer are underrepresented in clinical trials, an oncogeriatric approach is advocated to guide treatment decisions. However, the effect on outcomes is unclear. The aim of this study was to compare treatments and outcomes between patients treated in an oncogeriatric and a s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05860-7

    authors: de Boer AZ,van de Water W,Bastiaannet E,de Glas NA,Kiderlen M,Portielje JEA,Extermann M

    更新日期:2020-11-01 00:00:00